Table 3.
Impact of CMV IgG Titer on Overall Survival and Time to First Treatment
| OVERALL SURVIVAL | Median IgG titer (inter‐quartile range)a all patients | Median IgG titer (inter‐quartile range) alive patients | Median IgG titer (inter‐quartile range) deceased patients | Number of deaths in CMV positive individuals (%) | Hazards ratio (95% CI) | P value |
|---|---|---|---|---|---|---|
| Discovery cohort | 227.1 (113.8–503.4) | 234.7 (114.6–556.1) | 213.0 (105.2–440.7) | 49/198 (25%) | 0.95 (0.82–1.09) | 0.46 |
| Confirmatory cohort | 202.1 (103.9–357.1) | 196.9 (110.5–342.2) | 209.5 (93.2–404.9) | 75/179 (42%) | 1.02 (0.88–1.19) | 0.79 |
| Combined cohorts | 211.9 (106.8–434.6) | 211.9 (114.6–448.8) | 210.1 (98.3–433.1) | 124/377 (33%) | 1.01 (0.91–1.13) | 0.80 |
| TIME TO TREATMENT | Median IgG titer (inter‐quartile range)a all patients | Median IgG titer (inter‐quartile range) treated patients | Median IgG titer (inter‐quartile range) untreated patients | Number of patients treated in CMV positive individuals (%) | Hazards ratio (95% CI) | P value |
| Discovery cohort | 227.8 (118.5–506.5) | 234.7 (123.2–455.0) | 227.1 (107.0–522.7) | 63/185 (34%) | 0.99 (0.87–1.13) | 0.93 |
| Confirmatory cohort | 202.1 (103.9–357.1) | 204.0 (95.5–357.4) | 185.7 (105.7–363.0) | 86/179 (48%) | 1.02 (0.89–1.17) | 0.78 |
| Combined cohorts | 211.9 (107.1–445.6) | 213.0 (115.0–418.6) | 211.9 (107.1–445.6) | 149/364 (41%) | 1.00 (0.91–1.10) | 0.97 |
a
Titer is the base 2 log, to take account of the non‐linearity of the untransformed variable.